Is it accurate to classify ALS as a neuromuscular disorder?. (1st September 2020)

• Record Type: Journal Article
• Authors: van Es, Michael A.; Goedee, H. Stephan; Westeneng, Henk-Jan; Nijboer, Tanja C.W.; van den Berg, Leonard H.
• Is Part Of: Expert review of neurotherapeutics. Volume 20:Number 9(2020)
• Page Start: 895
• Page End: 906
• Publication Date: 2020-09-01
• Subjects: Amyotrophic lateral sclerosis (ALS) -- frontotemporal dementia (FTD) -- TDP-43 -- neurodegeneration; Neuropharmacology -- Periodicals; 615.7805
• DOI: 10.1080/14737175.2020.1806061
• Languages: English
• ISSNs: 1473-7175

Abstract

ABSTRACT: Introduction: Amyotrophic lateral sclerosis (ALS) is a fatal disorder characterized by the progressive loss of upper and lower motor neurons. ALS has traditionally been classified within the domain of neuromuscular diseases, which are a unique spectrum of disorders that predominantly affect the peripheral nervous system. However, over the past decades compounding evidence has emerged that there is extensive involvement of the central nervous system. Therefore, one can question whether it remains accurate to classify ALS as a neuromuscular disorder. Areas covered: In this review, the authors sought to discuss current approaches toward disease classification and how we should classify ALS based on novel insights from clinical, imaging, pathophysiological, neuropathological and genetic studies. Expert opinion: ALS exhibits the cardinal features of a neurodegenerative disease. Therefore, classifying ALS as a neuromuscular disease in the strict sense has become untenable. Diagnosing ALS however does require significant neuromuscular expertise and therefore neuromuscular specialists remain best equipped to evaluate this category of patients. Designating motor neuron diseases as a separate category in the ICD-11 is justified and adequately deals with this issue. However, to drive effective therapy development the fields of motor neuron disease and neurodegenerative disorders must come together.